Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic antibiotic presented as a intravesical solution for intravesical use. It treats non‑muscle invasive bladder cancer, typically after transurethral resection of bladder tumor.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin is used in the management of bladder cancer, acting as an intravesical chemotherapeutic agent. - Non‑muscle invasive bladder cancer: reduces recurrence after transurethral resection. - Carcinoma in situ of the bladder: provides local cytotoxic effect to eradicate residual disease. - High‑risk superficial bladder tumors: serves as adjuvant intravesical therapy to improve disease‑free survival.

Mitomycin administered intravesically may be associated with local and systemic adverse reactions. Common Side Effects: - Irritative bladder symptoms: dysuria, frequency, urgency. - Hematuria: visible blood in urine. - Nausea: occasional gastrointestinal upset. Serious or Rare Side Effects: - Severe cystitis: painful bladder inflammation requiring intervention. - Bladder fibrosis: scarring that may reduce bladder capacity. - Systemic myelosuppression: neutropenia or thrombocytopenia.

When using Mitomycin Medac, careful patient assessment and monitoring are essential. - Patient selection: use only in patients with confirmed non‑muscle invasive bladder cancer after complete resection. - Renal function: assess baseline renal function; avoid if severe impairment. - Urinary tract infection: treat active infection before instillation. - Hematuria: postpone treatment if gross hematuria persists. - Pregnancy and lactation: contraindicated; avoid exposure in pregnant or breastfeeding women. - Store at room temperature: keep in original container, protect from light and moisture.

Mitomycin may interact with other medicines; awareness of major and moderate interactions helps mitigate risk. Major Interactions (Avoid): - Concurrent nephrotoxic agents: may exacerbate renal toxicity. - Systemic chemotherapy with overlapping myelosuppressive effects: increase risk of bone marrow suppression. Moderate Interactions (Monitor Closely): - Anticoagulants: heightened risk of hematuria. - NSAIDs: may worsen renal function when combined. - Radiotherapy to the pelvis: potential additive bladder toxicity.